Compare Okta, Inc. (OKTA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Zoetis Inc — how do they compare? Okta, Inc. trades at $232.13 (market cap $38.50B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Okta, Inc. is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Zoetis Inc for 70 Days on average.
| OKTA | ZTS | |
|---|---|---|
Market Cap | $38.50B | $30.20B |
Volume | 2,479,621 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $232.13 | $147.53 |
52-Week Low | $62.93 | $69.09 |
Typical Hold Time | 44 Days | 70 Days |
Enterprise Value | $36.25B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages and strong analyst support (73.58% buy ratings). The company reported a net income of $28 million in 2025, marking a return to profitability after losses in prior years, with revenue growing to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
The outlook is positive due to earnings beats, AI-driven growth potential, and improving cash flow, but risks include high valuation multiples (P/E of 132.66) and competitive pressures in cybersecurity. The stock trades above the consensus price target of $201.30, suggesting near-term consolidation may occur despite long-term growth prospects.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
